Full Year Trading Update

Optima Health PLC

16 June 2026

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.

Optima Health plc

("Optima", the "Company", and, together with its subsidiaries, the "Group")

Full Year Trading Update

LONDON, UK, 16 June 2026, Optima Health (AIM: OPT), the UK's leading provider of technology enabled corporate health and wellbeing solutions, today announces an unaudited trading update ahead of the publication of the Group's results for the year ended 31 March 2026.

Highlights

·    Revenue for the year of approximately £121 million; 15% growth year-on-year (FY25: £105 million) in line with market expectations

·    Other income of £4.7 million recognised relating to a previously disclosed procurement matter

·    FY26 adjusted EBITDA expected to be c.10% ahead of previous market expectations as previously announced

·    Completion of transformational £100 million acquisition of PAM Healthcare Limited ("PAM") on 26 March 2026, significantly enhancing scale and capability of the Group

·    Integration activity is well underway with annualised synergies of £1.3 million already delivered as of 1 June 2026

·    New business annualised wins of £10.8 million in FY26 [Optima only](FY25: £27.2 million) with a strong pipeline of new potential opportunities across the enlarged group including PAM

·    Robust balance sheet with net debt (excluding leases) of £94.4 million as at 31 March 2026

Optima expects to report revenue for the full year of approximately £121 million, in line with market expectations, representing 15% growth versus FY25. As previously communicated, Optima expects FY26 adjusted EBITDA to be approximately 10% ahead of previous market expectations. Reflecting completion of the acquisition of PAM shortly prior to the year ended, the Group's net debt position (excluding leases) at 31 March 2026 was £94.4 million, comprising a cash balance of £21.6 million and £116 million of debt. Net debt at the end of May has reduced following repayment of the £30 million shareholder bridging loan associated with the acquisition of PAM, using net proceeds from the underwritten Open Offer equity raise which completed on 24 April 2026.

The Group has continued to make strong progress against its strategic objectives and medium‑term targets of achieving annual revenues of £200 million and £40 million of adjusted EBITDA. In line with the Group's strategy, Optima completed the transformational acquisition of PAM in March 2026 for total cash consideration of approximately £100 million. As one of the UK and Republic of Ireland's leading occupational health and wellness service providers, PAM is highly complementary and synergistic to Optima's existing operations. The integration of PAM is proceeding to plan and is expected to deliver significant revenue synergies, alongside operational and cost efficiencies. As of 1 June 2026 £1.3 million of annualised cost synergies have already been delivered.

The acquisition of PAM followed two strategic acquisitions by Optima during the first half of the year to further accelerate long-term growth and continue to increase the Group's market share, and broaden its capabilities, both in scope and geography.

Optima expects to report its Full Year Results for the year ended 31 March 2026 in August 2026.

Jonathan Thomas, Chief Executive Officer of Optima Health, said: "Optima's performance in FY26 demonstrates the momentum we are building as we deliver against our strategic objectives. Completing the acquisition of PAM during the year has expanded our capabilities and strengthened our ability to support customers across the UK and Ireland. As we look ahead, our priorities remain clear: maintaining high quality service delivery, progressing integration activities and our transformation programme, and advancing strategic initiatives to support the next phase of growth towards our stated ambition."

Enquiries

Optima Health Jonathan Thomas, CEO Heidi Giles, CFO [phone] [e-mail] Nominated Adviser and Joint Corporate Broker Panmure Liberum Limited Emma Earl / Will Goode/ Mark Rogers / Rupert Dearden Debt Advisory (sole debt adviser on the transaction): Dan Howlett / Ben Handler [phone] Joint Corporate Broker Cavendish Capital Markets Geoff Nash / Ben Jeynes / George Lawson / Julian Morse / Michael Johnson/ Nigel Birks + 44 (0)20 7220 0500 UK Financial PR Adviser ICR Healthcare Mary-Jane Elliott / Angela Gray / Lindsey Neville [e-mail]

About Optima Health

Optima Health is the UK's leading provider of occupational health and wellbeing services, delivering clinically led, technology-driven solutions to organisations across the public and private sectors. With a team of more than 1,600 including 800 clinicians, Optima Health supports millions of employees and operates from a network of more than 50 clinics nationwide.

In addition to its core UK market, Optima Health also operates in Ireland under Optima Health Ireland, providing occupational health services to clients nationwide.

For more information visit www.optimahealth.co.uk

 

END